The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 26, 2023
Filed:
Jul. 29, 2022
Applicant:
Gw Research Limited, Cambridge, GB;
Inventors:
Assignee:
GW Research Limited, Cambridge, GB;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/05 (2006.01); A61K 31/195 (2006.01); A61K 31/20 (2006.01); A61K 31/27 (2006.01); A61K 31/352 (2006.01); A61K 31/4015 (2006.01); A61K 31/4166 (2006.01); A61K 31/423 (2006.01); A61K 31/496 (2006.01); A61K 31/53 (2006.01); A61K 31/551 (2006.01); A61K 31/5513 (2006.01); A61K 31/5517 (2006.01); A61K 31/7048 (2006.01); A61K 36/185 (2006.01); A61K 45/06 (2006.01); A61K 31/165 (2006.01); A61K 31/19 (2006.01); A61K 31/197 (2006.01); A61K 31/35 (2006.01); A61K 31/36 (2006.01); A61K 47/10 (2017.01); A61K 47/26 (2006.01); A61K 47/44 (2017.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 31/444 (2006.01); A61K 31/515 (2006.01); A61K 31/55 (2006.01);
U.S. Cl.
CPC ...
A61K 31/05 (2013.01); A61K 9/0053 (2013.01); A61K 9/08 (2013.01); A61K 31/165 (2013.01); A61K 31/19 (2013.01); A61K 31/195 (2013.01); A61K 31/197 (2013.01); A61K 31/20 (2013.01); A61K 31/27 (2013.01); A61K 31/35 (2013.01); A61K 31/352 (2013.01); A61K 31/36 (2013.01); A61K 31/4015 (2013.01); A61K 31/4166 (2013.01); A61K 31/423 (2013.01); A61K 31/444 (2013.01); A61K 31/496 (2013.01); A61K 31/515 (2013.01); A61K 31/53 (2013.01); A61K 31/55 (2013.01); A61K 31/551 (2013.01); A61K 31/5513 (2013.01); A61K 31/5517 (2013.01); A61K 31/7048 (2013.01); A61K 36/185 (2013.01); A61K 45/06 (2013.01); A61K 47/10 (2013.01); A61K 47/26 (2013.01); A61K 47/44 (2013.01);
Abstract
The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of 'treatment-resistant epilepsy' (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).